Clinical Chemistry | LabMedica International The Clinical Chemistry channel updates the reader on tests, techniques, and research in the field - from routine assays to specialized tests on blood, urine, enzymes, lipids, hormones and more. https://www.labmedica.com Wed, 20 May 2026 18:53:56 +0100 FeedCreator 1.7.2 International Experts Recommend Ending Routine 'Corrected' Calcium Reporting https://www.labmedica.com/clinical-chemistry/articles/294810689/international-experts-recommend-ending-routine-corrected-calcium-reporting.html Guidelines recommend ending routine albumin-adjusted calcium reporting and prioritizing ionized calcium for key decisions. International Experts Recommend Ending Routine 'Corrected' Calcium Reporting - International Experts Recommend Ending Routine 'Corrected' Calcium Reporting Wed, 20 May 2026 10:44:36 +0100 Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths https://www.labmedica.com/clinical-chemistry/articles/294810628/long-term-data-show-psa-screening-modestly-reduces-prostate-cancer-deaths.html New data show PSA screening modestly cuts prostate cancer deaths but increases detection of earlier-stage disease. Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer DeathsIncreases Diagnoses - Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths Wed, 20 May 2026 00:17:18 +0100 Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively https://www.labmedica.com/clinical-chemistry/articles/294810583/urine-based-nanosensor-tracks-lung-cancer-and-fibrosis-noninvasively.html A new urine test tracks enzyme activity to support earlier, ongoing monitoring of lung cancer and pulmonary fibrosis. Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively - Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively Fri, 15 May 2026 11:19:55 +0100 Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection https://www.labmedica.com/clinical-chemistry/articles/294810479/blood-based-alzheimers-test-gains-ce-mark-for-amyloid-pathology-detection.html A new test measures pTau217 to rule in or rule out amyloid pathology, enabling earlier, less invasive Alzheimer’s assessment. Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection - Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection Thu, 14 May 2026 12:46:55 +0100 FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing https://www.labmedica.com/clinical-chemistry/articles/294810530/fda-cleared-assay-enables-comprehensive-automated-testosterone-testing.html Revvity receives FDA clearance for total testosterone assay enabling comprehensive automated testing. FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing - FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing Wed, 13 May 2026 16:30:13 +0100